{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:32:20Z","timestamp":1777379540181,"version":"3.51.4"},"reference-count":35,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T00:00:00Z","timestamp":1567123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["AIDS Research and Human Retroviruses"],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:p>\n                    Bone mineral density (BMD) declines due to tenofovir-containing pre-exposure prophylaxis (PrEP) have varied among PrEP demonstration projects, potentially related to variable adherence. Characterization of BMD changes in highly adherent individuals, estimated via tenofovir-diphosphate (TFV-DP) levels in dried blood spots (DBS), can assist clinicians when counseling patients. Cisgender men who have sex with men and transwomen in the optional dual-energy X-ray absorptiometry (DXA) substudy of a large, international, open-label PrEP demonstration project, the iPrEx-open-label extension (OLE) study underwent DXA scans and DBS collection every 24 weeks, with average weekly dosing adherence patterns (2, 4, and 7 doses\/week) estimated from validated TFV-DP cut-offs. The mean percent BMD change was estimated in strata of average weekly adherence by using a linear mixed-effects model to calculate the BMD decline in highly adherent individuals on PrEP for the first time. DXA\/DBS data were available for 254 individuals over a median of 24 weeks in iPrEx-OLE from June 2011 to December 2013. The percent decline in spine BMD was monotonically associated with strata of increasing average weekly adherence (\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    \u2009&lt;\u2009.001 trend); the\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    value for trends using hip BMD measurements was .07. Individuals with estimated daily adherence experienced a 1.2% decrease in spine BMD and a 0.5% drop in hip BMD. In highly adherent PrEP users, we found a lower-than-expected drop in BMD when compared with previous studies. This drop is likely not clinically significant for most PrEP users. However, for those at the highest risk of fracture who plan prolonged PrEP use, alternate PrEP strategies could be considered.\n                  <\/jats:p>","DOI":"10.1089\/aid.2018.0297","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T07:22:40Z","timestamp":1558596160000},"page":"788-793","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Impact of Estimated Pre-Exposure Prophylaxis (PrEP) Adherence Patterns on Bone Mineral Density in a Large PrEP Demonstration Project"],"prefix":"10.1177","volume":"35","author":[{"given":"Matthew A.","family":"Spinelli","sequence":"first","affiliation":[{"name":"Division of HIV, ID, and Global Medicine, University of California, San Francisco, San Francisco, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David V.","family":"Glidden","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter L.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of Colorado, Aurora, Colorado."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Division of HIV, ID, and Global Medicine, University of California, San Francisco, San Francisco, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa M.","family":"McMahan","sequence":"additional","affiliation":[{"name":"Department of Health Services, University of Washington, Seattle, Washington."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Defechereux","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Francisco, San Francisco, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Schechter","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valdil\u00e9a G.","family":"Veloso","sequence":"additional","affiliation":[{"name":"Evandro Chagas National Institute of Infectious Diseases, Rio de Janeiro, Brazil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suwat","family":"Chariyalertsak","sequence":"additional","affiliation":[{"name":"Research Institute for Health Sciences and Faculty of Public Health, Chiang Mai University, Chiang Mai, Thailand."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan V.","family":"Guanira","sequence":"additional","affiliation":[{"name":"Investigaciones Medicas en Salud, Lima, Peru."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda-Gail","family":"Bekker","sequence":"additional","affiliation":[{"name":"Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan P.","family":"Buchbinder","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Francisco, San Francisco, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M.","family":"Grant","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Francisco, San Francisco, California."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2019,8,30]]},"reference":[{"key":"e_1_3_3_2_2","first-page":"41","article-title":"Tenofovir-associated bone density loss","volume":"6","author":"Grigsby IF","year":"2010","unstructured":"Grigsby IF, , Pham L, , Mansky LM, , Gopalakrishnan R, , Mansky KC: Tenofovir-associated bone density loss. Ther Clin Risk Manag, 2010; 6:41\u201347.","journal-title":"Ther Clin Risk Manag"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001067"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001995"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ455"},{"key":"e_1_3_3_6_2","first-page":"53","article-title":"Characteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy","volume":"3","author":"Horizon AA","year":"2011","unstructured":"Horizon AA, , Joseph RJ, , Liao Q, , Ross ST, , Pakes GE: Characteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy. HIV AIDS (Auckl), 2011; 3:53\u201359.","journal-title":"HIV AIDS (Auckl)"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328351997f"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31821ecf4c"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32835192ae"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocd.2012.04.001"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001903"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw765"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001179"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000858"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023688"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ324"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001475"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2017.2007"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110711"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.8431"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-016-0341-9"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2016.09.056"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadohealth.2018.07.021"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506273"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033103"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0074314"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-018-0553-3"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70847-3"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix755"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01710-17"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(16)30153-9"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001615"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2018.0096"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-004-1734-y"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.7326\/M15-1361"},{"key":"e_1_3_3_36_2","volume-title":"et al","author":"Hare CB","year":"2019","unstructured":"Hare CB, , Coll J, , Ruane P, et al.: The phase 3 discover study: Daily F\/TAF or F\/TDF for HIV preexposure prophylaxis. Conference on Retroviruses and Opportunistic Infections, March 3\u20137, Seatle, 2019."}],"container-title":["AIDS Research and Human Retroviruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/aid.2018.0297","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/aid.2018.0297","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/aid.2018.0297","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:14:44Z","timestamp":1777367684000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/aid.2018.0297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,30]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1089\/aid.2018.0297"],"URL":"https:\/\/doi.org\/10.1089\/aid.2018.0297","relation":{},"ISSN":["0889-2229","1931-8405"],"issn-type":[{"value":"0889-2229","type":"print"},{"value":"1931-8405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,30]]}}}